Immupharma PLC Lupuzor Pivotal Phase III Study Update (6822I)
March 23 2018 - 3:00AM
UK Regulatory
TIDMIMM
RNS Number : 6822I
Immupharma PLC
23 March 2018
23 March 2018
ImmuPharma PLC
("ImmuPharma" or the "Company")
Lupuzor(TM) Pivotal Phase III Study Update
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and
development company announces that it has been informed by
Simbec-Orion, the contract research organisation conducting our
Lupuzor(TM) pivotal Phase III trial study, that 'database lock' is
expected on 6 April 2018, with top line results announced by
mid-April 2018.
Lupuzor(TM) is the Company's lead programme for the potential
breakthrough compound for Lupus, a life threatening autoimmune
disease.
Commenting on the trial update, Tim McCarthy, Chairman, said:
"With the continued robust safety record of Lupuzor(TM) achieved
over this trial, we look forward with confidence to reporting top
line results in the near future."
For more information on the trial please visit:
https://clinicaltrials.gov/ct2/show/NCT02504645
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
For further information please
contact:
+ 44 (0) 20
ImmuPharma plc (www.immupharma.com) 7152 4080
Tim McCarthy, Chairman
Lisa Baderoon, Head of Investor
Relations + 44 (0) 7721
Twitter: @immupharma 413496
Northland Capital Partners Limited
David Hignell, Dugald Carlean,
Jamie Spotswood, Corporate Finance +44 (0)20 3861
Rob Rees, Corporate Broking 6625
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCFKBDDCBKDNNB
(END) Dow Jones Newswires
March 23, 2018 03:00 ET (07:00 GMT)
Immupharma (LSE:IMM)
Historical Stock Chart
From Apr 2024 to May 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From May 2023 to May 2024